Your browser doesn't support javascript.
Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health.
Lo Presti, Elena; Nuzzo, Domenico; Al Mahmeed, Wael; Al-Rasadi, Khalid; Al-Alawi, Kamila; Banach, Maciej; Banerjee, Yajnavalka; Ceriello, Antonio; Cesur, Mustafa; Cosentino, Francesco; Firenze, Alberto; Galia, Massimo; Goh, Su-Yen; Janez, Andrej; Kalra, Sanjay; Kapoor, Nitin; Kempler, Peter; Lessan, Nader; Lotufo, Paulo; Papanas, Nikolaos; Rizvi, Ali A; Sahebkar, Amirhossein; Santos, Raul D; Stoian, Anca P; Toth, Peter P; Viswanathan, Vijay; Rizzo, Manfredi.
  • Lo Presti E; Institute for Biomedical Research and Innovation, National Research Council, Palermo, Italy. Electronic address: elena.lopresti@cnr.it.
  • Nuzzo D; Institute for Biomedical Research and Innovation, National Research Council, Palermo, Italy.
  • Al Mahmeed W; Heart and Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.
  • Al-Rasadi K; Medical Research Center, Sultan Qaboos University, Muscat, Oman.
  • Al-Alawi K; Department of Training and Studies, Royal Hospital, Ministry of Health, Muscat, Oman.
  • Banach M; Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.
  • Banerjee Y; Department of Biochemistry, Mohamed Bin Rashid University, Dubai, United Arab Emirates.
  • Ceriello A; IRCCS MultiMedica, Milan, Italy.
  • Cesur M; Clinic of Endocrinology, Ankara Güven Hospital, Ankara, Turkey.
  • Cosentino F; Unit of Cardiology, Karolinska Institute and Karolinska University Hospital, University of Stockholm, Sweden.
  • Firenze A; Unit of Research and International Cooperation, University Hospital of Palermo, Italy.
  • Galia M; Department of Biomedicine, Neurosciences and Advanced Diagnostics (Bind), University of Palermo, Italy.
  • Goh SY; Department of Endocrinology, Singapore General Hospital, Singapore.
  • Janez A; Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Slovenia.
  • Kalra S; Department of Endocrinology, Bharti Hospital & BRIDE, Karnal, India.
  • Kapoor N; Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
  • Kempler P; Department of Medicine and Oncology, Semmelweis University, Budapest, Hungary.
  • Lessan N; The Research Institute, Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates.
  • Lotufo P; Center for Clinical and Epidemiological Research, University Hospital, University of São Paulo, Brazil.
  • Papanas N; Diabetes Center, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece.
  • Rizvi AA; Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
  • Sahebkar A; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Science
  • Santos RD; Heart Institute (InCor) University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil; Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
  • Stoian AP; Faculty of Medicine, Diabetes, Nutrition and Metabolic Diseases, Carol Davila University, Bucharest, Romania.
  • Toth PP; Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Viswanathan V; Diabetes Research Centre, Chennai, India.
  • Rizzo M; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Italy. Electronic address: manfredi.rizzo@unipa.it.
Biochim Biophys Acta Mol Basis Dis ; 1868(12): 166559, 2022 12 01.
Article in English | MEDLINE | ID: covidwho-2041586
ABSTRACT
Obesity, type 2 diabetes (T2DM), hypertension (HTN), and Cardiovascular Disease (CVD) often cluster together as "Cardiometabolic Disease" (CMD). Just under 50% of patients with CMD increased the risk of morbidity and mortality right from the beginning of the COVID-19 pandemic as it has been reported in most countries affected by the SARS-CoV2 virus. One of the pathophysiological hallmarks of COVID-19 is the overactivation of the immune system with a prominent IL-6 response, resulting in severe and systemic damage involving also cytokines such as IL2, IL4, IL8, IL10, and interferon-gamma were considered strong predictors of COVID-19 severity. Thus, in this mini-review, we try to describe the inflammatory state, the alteration of the adipokine profile, and cytokine production in the obese state of infected and not infected patients by SARS-CoV2 with the final aim to find possible influences of COVID-19 on CMD and CVD. The immunological-based discussion of the molecular processes could inspire the study of promising targets for managing CMD patients and its complications during COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus, Type 2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Biochim Biophys Acta Mol Basis Dis Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus, Type 2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Biochim Biophys Acta Mol Basis Dis Year: 2022 Document Type: Article